About Olivier

With an economics and sociology background, Olivier Maguet has been involved in the field of HIV/AIDS and Harm Reduction since the end of the ‘80s. In 2006, he joined Médecins du Monde/Doctors of the World as head of mission in Afghanistan to set up a Harm Reduction program in Kabul. From 2010 to 2016, he has been elected as Board Member as key referent for Harm Reduction in MdM network. Since 2014 he has been campaigning in MdM on drug pricing issue in OECD countries. Within his involvement, he has led two opposition procedures against Gilead’s sofosbuvir patents at European Patent Office – the first one having led to a core amendment of the prodrug patent in October 2016. He he’s now appointed as drug pricing campaign responsible for MdM. Alongside his voluntary involvement in MdM, Olivier Maguet is an independent consultant in the field of Harm Reduction and drug addiction.

This speaker will be presenting at the following session(s)

  • How to make hepatitis treatment more affordable and accessible

    Panel

    Day: 2 November

    Time: 15:30

    This closing panel session examines the key barriers and current strategies to scale up access to hepatitis treatment.

    Chair: Liudmyla Maistat, Medicines Patent Pool

    Chair: Charles Gore, World Hepatitis Alliance

    Presentations:

    • WHO's vision of access to hepC treatment.
    • Barriers to access and access strategies.
    • Ellen ‘t Hoen, University Medical Centre Groningen
    • Patent opposition.
    • Olivier Maguet, Médecins du Monde
    • Compulsory licensing.
    • Direct price negotiations.
    • Medicines Patent Pool’s approach to access.
    • Greg Perry, Medicines Patent Pool
    • Open discussion with audience.

    Objectives:

    • To provide an overview of key barriers to access hepatitis C treatment.
    • To review different approaches to overcoming access barriers and the progress made.